Illustration: Sarah Grillo/Axios

Amgen and Novartis jointly developed and sold the first FDA-approved drug to prevent migraines, which hit the market last year. But now their alliance is crumbling and they're suing each other.

The big picture: Everyone is so mad. These pharma giants are throwing every legal punch possible because there is so much money at stake.

  • Because Aimovig was the first in this class of migraine drugs to get FDA approval, it got the upper hand and controls 53% of the market.
  • U.S. sales of Aimovig were $119 million in 2018, but Wall Street analysts think sales could hit almost $2 billion by 2025.

The intrigue: Everything revolves around the contracts that Amgen and Novartis signed, which outlined how they would collaborate on research and marketing for Aimovig.

  • Amgen terminated the contracts on April 2, alleging a subsidiary of Novartis violated the terms by helping another company, Alder BioPharmaceuticals, make a competing migraine drug. Novartis admitted this after the fact, yet said it would still help Alder for another 5 years, according to Amgen's lawsuit.
  • Novartis denies the claims, arguing it didn't significantly breach their agreements because Alder's pending product isn't a true competitor. Instead, Novartis asserted Amgen is inappropriately ending the partnership "to keep the Aimovig profits for itself" and before Novartis "has come close to earning a return on its investment."

Go deeper:

Go deeper

Updated 1 hour ago - Politics & Policy

U.S. officials: Iran and Russia aim to interfere in election

Iran and Russia have obtained voter registration information that can be used to undermine confidence in the U.S. election system, Director of National Intelligence John Ratcliffe announced at a press conference Wednesday evening.

Why it matters: The revelation comes roughly two weeks before Election Day. Ratcliffe said Iran has sent threatening emails to Democratic voters this week in states across the U.S. and spread videos claiming that people can vote more than once.

Updated 2 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Politics: Senate Democrats block vote on McConnell's targeted COVID relief bill McConnell urges White House not to strike stimulus deal before election.
  2. Economy: Why the stimulus delay isn't a crisis (yet).
  3. Health: New York reports most COVID cases since MayStudies show drop in coronavirus death rate — The next wave is gaining steam.
  4. Education: Schools haven't become hotspots — San Francisco public schools likely won't reopen before the end of the year.
  5. World: Spain becomes first nation in Western Europe to exceed 1 million cases.
Updated 3 hours ago - Politics & Policy

Supreme Court blocks Alabama curbside voting measure

Photo: Mark Wilson/Getty Images

The Supreme Court on Wednesday evening blocked a lower court order that would have allowed voters to cast ballots curbside at Alabama polling places on Election Day.

Whit it matters: With less than two weeks until Election Day, the justices voted 5-3 to reinstate the curbside voting ban and overturn a lower court judge's ruling designed to protect people with disabilities during the coronavirus pandemic.